About the Authors
- Sabrina J. Merat
-
Affiliation AIMM Therapeutics, Amsterdam, the Netherlands
- Richard Molenkamp
-
Affiliation Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands
- Koen Wagner
-
Affiliation AIMM Therapeutics, Amsterdam, the Netherlands
- Sylvie M. Koekkoek
-
Affiliation Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands
- Dorien van de Berg
-
Affiliation AIMM Therapeutics, Amsterdam, the Netherlands
- Etsuko Yasuda
-
Affiliation AIMM Therapeutics, Amsterdam, the Netherlands
- Martino Böhne
-
Affiliation AIMM Therapeutics, Amsterdam, the Netherlands
- Yvonne B. Claassen
-
Affiliation AIMM Therapeutics, Amsterdam, the Netherlands
- Bart P. Grady
-
Affiliation Department of Infectious Diseases Research and Prevention, Cluster of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
- Maria Prins
-
Affiliations Department of Infectious Diseases Research and Prevention, Cluster of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands, Department of infectious diseases, Academic Medical Center, Amsterdam, the Netherlands
- Arjen Q. Bakker
-
Affiliation AIMM Therapeutics, Amsterdam, the Netherlands
- Menno D. de Jong
-
Affiliation Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands
- Hergen Spits
-
Affiliation AIMM Therapeutics, Amsterdam, the Netherlands
- Janke Schinkel
-
Contributed equally to this work with: Janke Schinkel, Tim Beaumont
Affiliation Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands
- Tim Beaumont
-
Contributed equally to this work with: Janke Schinkel, Tim Beaumont
* E-mail: tbeaumont@aimmtherapeutics.com
Affiliation AIMM Therapeutics, Amsterdam, the Netherlands
Competing Interests
We would like to disclose that S.J.M, K.W., D.V.B., E.Y., M.B., Y.B.C., A.Q.B., H.S. and T.B. are employees and S.J.M, K.W., E.Y., M.B., Y.B.C., A.Q.B., H.S. and T.B. are shareholders of AIMM Therapeutics. Materials have been generated by a for profit company, AIMM Therapeutics which makes research reagents available for academic research under conditions outlined in its Material Transfer Agreement (http://www.aimmtherapeutics.com/partnering/academic-collaboration/). This does not alter our adherence to PLOS ONE policies on sharing data and materials. Furthermore, S.J.M. received travel grants from the international symposium on Hepatitis C virus and related viruses. M.D.J. was a member of the AIMM scientific advisory board.
Author Contributions
Conceptualization: SJM RM HS JS TB. Funding acquisition: MDJ HS JS TB. Investigation: SJM KW DB EY MB YBC AQB. Methodology: SJM RM KW TB. Project administration: JS TB. Resources: RM KW SMK MP BPG MB YBC AQB HS MDJ JS. Supervision: SJM AQB RM JS TB. Validation: SJM KW DB SMK. Visualization: SJM KW. Writing – original draft: SJM RM KW AQB JS TB. Writing – review & editing: SJM RM MP BPG MDJ JS HS TB.